Search

Author/Creator Janssen, M

8. P160 The first phase 2A proof-of-concept study of a selective NLRP3 inflammasome inhibitor, dapansutrile™ (OLT1177™), in acute gout. (March 2019)

Authors:
Jansen, TL; Klück, V; Janssen, M; Comarniceanu, A; Efdé, M; Scribner, CL; Barrow, RB; Skouras, DB; Dinarello, CA; Joosten, LA
Journal:
Annals of the rheumatic diseases
Issue:
Volume 78(2019)Supplement 1
Page Start:
A70
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Patients with gout have short telomeres compared with healthy participants: association of telomere length with flare frequency and cardiovascular disease in gout. Issue 7 (27th March 2017)

Authors:
Vazirpanah, N; Kienhorst, L B E; Van Lochem, E; Wichers, C; Rossato, M; Shiels, P G; Dalbeth, N; Stamp, L K; Merriman, T R; Janssen, M; Radstake, T R D J; Broen, J CA
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76:Issue 7(2017)
Page Start:
1313
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. Issue 12 (13th May 2005)

Authors:
van Reeuwijk, J; Janssen, M; van den Elzen, C; Beltran-Valero de Bernabé, D; Sabatelli, P; Merlini, L; Boon, M; Scheffer, H; Brockington, M; Muntoni, F; Huynen, M A; Verrips, A; Walsh, C A; Barth, P G; Brunner, H G; van Bokhoven, H
Journal:
Journal of medical genetics
Issue:
Volume 42:Issue 12(2005)
Page Start:
907
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗